Skip to main content

Palisade Bio, Inc. (PALI)

NASDAQ: PALI · IEX Real-Time Price · USD
2.81
+0.02 (0.72%)
After-hours:Oct 25, 2021 7:11 PM EDT
2.79
0.18 (6.90%)
At close: Oct 25, 4:00 PM
Market Cap34.52M
Revenue (ttm)5,000
Net Income (ttm)-40.77M
Shares Out8.83M
EPS (ttm)-0.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume695,138
Open2.61
Previous Close2.61
Day's Range2.60 - 2.92
52-Week Range2.27 - 16.02
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 10, 2021

About PALI

Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The compa...

IndustryBiotechnology
Founded1996
CEOI. Richard Garr
Employees7
Stock ExchangeNASDAQ
Ticker SymbolPALI
Full Company Profile

Financial Performance

In 2020, Palisade Bio's revenue was $13,520, a decrease of -12.17% compared to the previous year's $15,394. Losses were -$16.27 million, 94.8% more than in 2019.

Financial Statements

News

Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders

CARLSBAD, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharma company advancing oral therapies that help patients with acute and chronic gastrointestinal ...

3 days ago - GlobeNewsWire

4 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:FPAYHCWBHUSA
1 month ago - Benzinga

Palisade Bio Reports Second Quarter Financial Results and Provides Business Update

CARLSBAD, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a late-stage biopharma company advancing therapies for acute and chronic gastrointest...

2 months ago - GlobeNewsWire

Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center

CARLSBAD, Calif., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a late‐stage biopharma company advancing therapies for acute and chronic gastroin...

2 months ago - GlobeNewsWire

Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accel...

Statistically significant 1.1-day acceleration in return of bowel function

2 months ago - GlobeNewsWire

Palisade Bio, University of California Team Up For Target Identification, Discovery, Development

Palisade Bio Inc (NASDAQ: PALI) has entered into an exclusive license with the Regents of the University of California, expanding its technology for detecting enzymatic protease activity in human clinic...

3 months ago - Benzinga

Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage ...

Former Leading BioSciences Chairman and Retired Board-Certified Surgeon, Dr. David Berry to Serve as Chair Former Leading BioSciences Chairman and Retired Board-Certified Surgeon, Dr. David Berry to Ser...

4 months ago - GlobeNewsWire

Palisade Bio Stock Shoots Up On FDA Fast Track Tag For LB1148 For Reduction of Post-Operative Adhesions

The FDA has granted Fast Track Designation to Palisade Bio Inc's (NASDAQ: PALI) investigational drug LB1148, which has the potential to be the first oral treatment to reduce adhesions following abdomina...

5 months ago - Benzinga

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic...

LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery

5 months ago - GlobeNewsWire

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China

Topline results expected in H1-2021 Topline results expected in H1-2021

5 months ago - GlobeNewsWire

Palisade Bio Hosting Key Opinion Leader Webinar on LB1148, an Oral Serine Protease Inhibitor for Postoperative GI Dys...

Webinar on Thursday, May 13th @ 1pm ET Webinar on Thursday, May 13th @ 1pm ET

5 months ago - GlobeNewsWire

Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc.

GERMANTOWN, Md., April 26, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), disclosed on April 23, 2021, the passing of the final proposal required for approval of...

5 months ago - PRNewsWire

Seneca Biopharma's Merger Partner Leading BioSciences' Lead Asset Shows Efficacy In Lower Post-Surgical Adhesions

Privately-held Leading BioSciences Inc entered into a definitive agreement for a reverse merger with Seneca Biopharma Inc (NASDAQ: SNCA) has announced data from an open-label gastrointestinal (GI) surge...

6 months ago - Benzinga

Leading BioSciences Provides Update to Seneca Biopharma, Inc. Stockholders on Merger Closing Process Following Virtua...

Video message details merger closing process following completion of the April 23 virtual Special Meeting as well as next planned milestones for the merged company to be renamed Palisade Bio

6 months ago - GlobeNewsWire

Seneca Biopharma, Inc. Announces (i) Voting Results from the Special Meeting of Stockholders and (ii) New Special Mee...

GERMANTOWN, Md., April 12, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), announced the preliminary voting results of its Special Meeting of Stockholders on Apri...

6 months ago - PRNewsWire

Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca B...

Video message explains the multiple benefits of the proposed merger and provides an overview of the substantial market opportunity for the combined company to be named Palisade Bio

6 months ago - GlobeNewsWire

Leading BioSciences Encourages Seneca Biopharma Stockholders to Vote “FOR” Proposed Merger

Combined company, to be named Palisade Bio, will be well-positioned to leverage its compelling therapeutics pipeline, strong cash position, and accomplished management and Board to maximize stockholder ...

6 months ago - GlobeNewsWire

Seneca Announces New Special Meeting Date of April 9, 2021

GERMANTOWN, Md., March 24, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) (the "Company") today announced that the Company adjourned its special meeting of stockholders scheduled for Wednesd...

7 months ago - PRNewsWire

Seneca Biopharma Reports 2020 Yearend Results

GERMANTOWN, Md., March 22, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today r...

7 months ago - PRNewsWire

SNCA Stock: Seneca Biopharma Shares Rocket Ahead of Merger, Reverse Stock Split Meeting

Seneca Biopharma (SNCA) stock is on the rise as investors prepare for an upcoming meeting covering a merger and reverse stock split. The post SNCA Stock: Seneca Biopharma Shares Rocket Ahead of Merger, ...

Other symbols:SNDLTWTR
7 months ago - InvestorPlace

Independent Advisory Firm ISS Recommends Seneca Biopharma, Inc. Stockholders Vote for Proposed Merger and Reverse Sto...

GERMANTOWN, Md., March 17, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS") has r...

7 months ago - PRNewsWire

SHAREHOLDER ALERT: WeissLaw LLP Reminds CLGX, VGAC, SNCA, and RNET Shareholders About Its Ongoing Investigations

NEW YORK, March 11, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights o...

Other symbols:CLGX
7 months ago - PRNewsWire

Seneca Biopharma, Inc. Announces Top Line Data from Phase 2 Clinical Study in China for the Treatment of Ischemic Stroke

GERMANTOWN, Md., Jan. 20, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today an...

9 months ago - PRNewsWire

Why Regeneron, Jaguar Health And Seneca Are Moving Today

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringing the tota...

Other symbols:JAGXREGN
9 months ago - Benzinga

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Seneca Biopharma, Inc. - SNCA

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Buildingin New York City...

10 months ago - PRNewsWire